186 related articles for article (PubMed ID: 19240718)
1. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.
Quaye L; Song H; Ramus SJ; Gentry-Maharaj A; Høgdall E; DiCioccio RA; McGuire V; Wu AH; Van Den Berg DJ; Pike MC; Wozniak E; Doherty JA; Rossing MA; Ness RB; Moysich KB; Høgdall C; Blaakaer J; ; Easton DF; Ponder BA; Jacobs IJ; Menon U; Whittemore AS; Krüger-Kjaer S; Pearce CL; Pharoah PD; Gayther SA
Br J Cancer; 2009 Mar; 100(6):993-1001. PubMed ID: 19240718
[TBL] [Abstract][Full Text] [Related]
2. The effects of common genetic variants in oncogenes on ovarian cancer survival.
Quaye L; Gayther SA; Ramus SJ; Di Cioccio RA; McGuire V; Hogdall E; Hogdall C; Blaakr J; Easton DF; Ponder BA; Jacobs I; Kjaer SK; Whittemore AS; Pearce CL; Pharoah PD; Song H
Clin Cancer Res; 2008 Sep; 14(18):5833-9. PubMed ID: 18794094
[TBL] [Abstract][Full Text] [Related]
3. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
Schönleben F; Allendorf JD; Qiu W; Li X; Ho DJ; Ciau NT; Fine RL; Chabot JA; Remotti HE; Su GH
Pancreas; 2008 Mar; 36(2):168-72. PubMed ID: 18376308
[TBL] [Abstract][Full Text] [Related]
4. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.
Kang M; Shen XJ; Kim S; Araujo-Perez F; Galanko JA; Martin CF; Sandler RS; Keku TO
Cancer Biomark; 2013; 13(5):359-66. PubMed ID: 24440976
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
6. Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Bruckman KC; Schönleben F; Qiu W; Woo VL; Su GH
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Nov; 110(5):632-7. PubMed ID: 20813562
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA alterations in Middle Eastern ovarian cancers.
Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
[TBL] [Abstract][Full Text] [Related]
9. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
[TBL] [Abstract][Full Text] [Related]
11. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
Xu RF; Sun JP; Zhang SR; Zhu GS; Li LB; Liao YL; Xie JM; Liao WJ
Biomed Pharmacother; 2011 Feb; 65(1):22-6. PubMed ID: 21051183
[TBL] [Abstract][Full Text] [Related]
12. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
[TBL] [Abstract][Full Text] [Related]
13. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
14. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
15. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
[TBL] [Abstract][Full Text] [Related]
16. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
17. Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer.
Quaye L; Tyrer J; Ramus SJ; Song H; Wozniak E; DiCioccio RA; McGuire V; Høgdall E; Høgdall C; Blaakaer J; Goode EL; Schildkraut JM; Easton DF; Krüger-Kjaer S; Whittemore AS; Gayther SA; Pharoah PD
PLoS One; 2009 Jun; 4(6):e5983. PubMed ID: 19543528
[TBL] [Abstract][Full Text] [Related]
18. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
Li HT; Lu YY; An YX; Wang X; Zhao QC
Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
Katsios C; Ziogas DE; Roukos DH
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
[No Abstract] [Full Text] [Related]
20. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
